These innovative molecules represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose levels. https://royfkcq916336.vblogetin.com/45138469/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide